Mark Mullikin

Mr. Mullikin was appointed Chief Financial Officer of Vedanta in February 2021. He brings with him 25 years of experience raising and deploying capital for life sciences companies, most recently at Editas Medicine, where he served as Vice President, Finance and Investor Relations, and was involved in raising $700 million of equity capital.

Prior to this role, Mr. Mullikin worked for Novartis, focusing on financial and strategic planning as well as health economics and pricing. Before Novartis, he was a healthcare equity analyst at Adage Capital Management and Piper Sandler and began his career in the finance and strategy practice at Deloitte Consulting.

Mr. Mullikin earned his M.B.A. in finance from the MIT Sloan School of Management and his B.A. in economics from the University of Chicago.